ExpreS2ion Biotechnologies – Rights Issue 2024

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

ExpreS2ion Biotechnologies is carrying out a rights issue with preferential rights for existing shareholders, amounting to approximately SEK 60 million. The company published its prospectus the 5 June 2024.

CEO Bent U. Frandsen and CFO Keith Alexander will join us on 14 June at 11.00 and take a deeper dive into details of the rights issue and warrant programs, timetable, rationale for the capital raise, and use of proceeds.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 14.16, 7 June 2024.